%D9%81%D9%88%D9%86%D8%AF%D8%A7%D8%A8%D8%A7%D8%B1%D9%8A%D9%86%D9%88%D9%83%D8%B3FondaparinuxFondaparinuxFondaparinuxFondaparinuxFondaparinux%E3%83%95%E3%82%A9%E3%83%B3%E3%83%80%E3%83%91%E3%83%AA%E3%83%8C%E3%82%AF%E3%82%B9FondaparinuxFondaparynuksFondaparinux_s%C3%B3dico%D0%A4%D0%BE%D0%BD%D0%B4%D0%B0%D0%BF%D0%B0%D1%80%D0%B8%D0%BD%D1%83%D0%BA%D1%81FondaparinuksFondaparinuksFondaparinuks%D0%A4%D0%BE%D0%BD%D0%B4%D0%B0%D0%BF%D0%B0%D1%80%D0%B8%D0%BD%D1%83%D0%BA%D1%81Q27077698
about
P3781
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in CancerSafety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU PatientsEffectiveness of Blood Clot Medication With Concomitant Blood Pressure MedicationAnticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous ThromboembolismDetermination of Residual Anticoagulatory Effects of FondaparinuxFondaparinux in Critically Ill Patients With Renal FailureSuperficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus FondaparinuxSpecial Drug Use Investigation (Retrospective) for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg)Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism TreatmentComparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related SurgerySpecial Drug Use Investigation for ARIXTRA® (Fondaparinux) InjectionRetrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type IIProspective Evaluation of Efficacy and Safety of Fondaparinux in Surgical Cancer Patients, Risk Factors for ThromboembolismIncreased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19
P4844
The Fondaparinux Paradox: Fondaparinux-Related Heparin-induced Thrombocytopenia.Fondaparinux in heparin-induced thrombocytopenia: A decade's worth of clinical experienceFondaparinux pentasaccharide reduces sepsis coagulopathy and promotes survival in the baboon model of Escherichia coli sepsisMonitoring Fondaparinux in the Setting of Antithrombin DeficiencyHeparin-induced thrombocytopenia treated with fondaparinux: single center experienceThe clinical use of Fondaparinux: A synthetic heparin pentasaccharideFondaparinux Significantly Reduces Postoperative Venous Thromboembolism After Body Contouring Procedures Without an Increase in Bleeding Complications
P921
Q61862192-B3D54CEE-0645-47D0-8616-6022D9FDCD44Q61917756-6373B0DE-14AE-4D7D-8AF7-806CE99127E5Q61921616-BBE71CB4-69BB-4A54-8EB9-8A98E00C8E59Q61921675-A1D2CEF1-3236-444C-B195-8EFB7883D834Q61936031-AC8AEF8E-C292-45D2-99DB-94DC46921322Q61956156-3F57B378-A802-4529-B5D4-74F2CDC9CEA6Q61957776-5796B765-0B9E-412B-8E60-7DFE6957254FQ63320565-964D114B-E85A-4166-8030-38F0F0CA6853Q63320570-794650BA-0394-46EA-AE03-420AA81DBD3AQ63321786-209E57E8-5B91-4463-9B05-3966CD657256Q63322209-2BF207D8-B397-4F0D-9D6C-3D919AC5D0EBQ63336804-FA0351B7-2E7F-4DA8-AEA3-7E21C47151DBQ86289869-0E4DFC4A-2A9A-4053-BE39-180F4FD415C2Q92392136-0305AEF2-A819-4156-8FDA-28CB98174FF6Q92548929-55336D2D-6052-454E-8FF8-B82FED40CCC5
P4844
Q55317873-8090468C-8978-48AF-B873-A1A495C538BAQ60920117-A4BFE31A-8EBD-4D5B-BDF4-A9387AA4EBEEQ90251579-23C59EF6-F9B5-4E90-A7DE-D7688D22299AQ91250017-6BE6A527-813A-4760-AF34-90478B09DFFBQ91541001-0399D54B-8E9D-4ABD-8639-D00D80296D08Q91575516-46FA46E2-025F-4F7C-A0A5-1226EFED6389Q93100984-D290324F-6B0E-4A0B-9B35-648DC6FDE5A8
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
component quimic
@oc
name
Fondaparinux
@de
fondaparinuks
@nn
fondaparinux
@en
磺達肝素
@zh
type
label
Fondaparinux
@de
fondaparinuks
@nn
fondaparinux
@en
磺達肝素
@zh
altLabel
Arixtra®
@en
Natural heparin pentasaccharide
@en
prefLabel
Fondaparinux
@de
fondaparinuks
@nn
fondaparinux
@en
磺達肝素
@zh
P2175
P638
P486
P592
P6366
P661
P662
P683
P1579
P1748
P2017
CO[C@H]1O[C@H](COS(O)(=O)=O)[C ...... O)=O)[C@H](O)[C@H]1NS(O)(=O)=O
P2067
P2115
N0000148733
P231
104993-28-4
P233
COC1C(C(C(C(O1)COS(=O)(=O)O)OC ...... )O)O)OS(=O)(=O)O)O)NS(=O)(=O)O
P235
KANJSNBRCNMZMV-ABRZTLGGSA-N